Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 11, 2019
Reporting Period: Single event date (March 11, 2019)
Business Context: The registrant is an emerging growth company incorporated in Nevada. This filing serves as a Regulation FD disclosure regarding the publication of product information on the company's website.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of a specific event and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing discloses the release of "Product Information" via the company website, attached as Exhibit 99.1.
Guidance, Outlook, and Risks
- Management Commentary: The company published product information on its website on March 11, 2019.
- Regulatory Status: The information in this report is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Unusual Items: None reported beyond the standard Regulation FD disclosure.
Key Facts for Investor Verification
- Verify the content of the "Product Information Release" attached as Exhibit 99.1 to understand the specific product updates.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that this filing does not constitute a representation that the information is material investor information not otherwise publicly available.